Immacule Lifesciences Private Limited – FDA 483, Mar 14, 2023
An FDA inspection of Immacule Lifesciences Private Limited, a sterile drug manufacturer in Thanthuwal, India, revealed significant deficiencies in aseptic processing and quality control. Observations included a lack of established and followed procedures to prevent microbiological contamination during sterile drug production, and an inadequate quality control unit failing to properly approve and reject procedures and specifications, as evidenced by issues with change control and inaccurate particle counter listings.
ID · be36de17-8c23-4444-b7d9-6adc8c0ea6a1
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.